Abstract 1838P
Background
The prognostic value of neutrophil-to-lymphocyte ratio (NLR) and absolute lymphocyte count (ALC) in patients with mCRPC treated with prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has not been studied. Here, we assessed the association of NLR and ALC with [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) treatment outcomes in patients from the VISION study.
Methods
Adults with PSMA-positive mCRPC received 177Lu-PSMA-617 (7.4 GBq every 6 weeks, ≤ 6 cycles) + standard of care (SoC), or SoC alone. In this post hoc analysis, patients were categorized by NLR < 3 vs ≥ 3 and ALC < 1.0 × 103/μl vs ≥ 1.0 × 103/μl at baseline. Associations with overall survival (OS) and radiographic progression-free survival (rPFS) were assessed using the Kaplan–Meier method. Hazard ratios (HR) were estimated using Cox proportional hazards models.
Results
NLR and ALC data were available for a subset of patients (Table). Baseline characteristics were well balanced across subgroups. At baseline, median NLR was 3.8 vs 4.0 and median ALC was 1.06 × 103/μl and 1.0 × 103/μl, for 177Lu-PSMA-617 + SoC vs SoC alone, respectively. Shorter OS and rPFS were observed with higher NLR and lower ALC in each treatment arm (Table). 177Lu-PSMA-617 + SoC prolonged OS and rPFS vs SoC alone in all subgroups (Table). More patients with baseline NLR ≥ 3 reported serious adverse events (177Lu-PSMA-617 + SoC, 41.0%; SoC, 28.7%) than those with NLR < 3 (30.7%; 24.1%).
Table: 1838P
OS and rPFS by baseline NLR and ALC
NLR < 3 | NLR ≥ 3 | ALC < 1.0 K/μL | ALC ≥ 1.0 K/μL | ||||||
177Lu-PSMA-617 + SoC | SoC | 177Lu-PSMA-617 + SoC | SoC | 177Lu-PSMA-617 + SoC | SoC | 177Lu-PSMA-617 + SoC | SoC | ||
OS | Available data, n (%), | 189 (34.3) | 58 (20.7) | 324 (58.8) | 143 (51.1) | 224 (40.7) | 92 (32.9) | 289 (52.5) | 109 (38.9) |
Median, months | 19.2 | 14.8 | 14.2 | 10.6 | 13.5 | 10.4 | 17.8 | 13.3 | |
HR (95% CI) | 0.73 (0.49, 1.08) | 0.68 (0.54, 0.85) | 0.69 (0.52, 0.92) | 0.65 (0.49, 0.86) | |||||
rPFS | Available data, n (%) | 136 (35.3) | 50 (25.5) | 232 (60.3) | 114 (58.2) | 160 (41.6) | 77 (39.3) | 208 (54.0) | 87 (44.4) |
Median, months | 10.8 | 6.0 | 8.7 | 2.7 | 8.0 | 3.5 | 10.8 | 3.6 | |
HR (95% CI) | 0.66 (0.39, 1.09) | 0.38 (0.28, 0.51) | 0.46 (0.32, 0.66) | 0.43 (0.30, 0.61) |
CI, confidence interval
Conclusions
NLR ≥ 3 and ALC < 1.0 × 103/μl at baseline are prognostic for poor efficacy outcomes in patients with mCRPC in VISION. Treatment with 177Lu-PSMA-617 improved OS and rPFS vs SoC alone regardless of baseline NLR/ALC. Additional analyses including change in NLR and ALC during treatment, associations with prostate-specific antigen and biochemical and objective response rates will be presented.
Clinical trial identification
EudraCT 2018-000459-41.
Editorial acknowledgement
Under direction of the authors, Shufei Song, PhD, of Oxford PharmaGenesis, Oxford, UK provided medical writing support, which was funded by Novartis, in accordance with Good Publication Practice (GPP 2022) guidelines (https://www.ismpp.org/gpp-2022).
Legal entity responsible for the study
Novartis.
Funding
Novartis.
Disclosure
X.X. Wei: Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Institutional, Coordinating PI: BMS. K.N.N. Chi: Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Janssen, Point Biopharma, Roche; Financial Interests, Personal, Advisory Board: AstraZeneca, AstraZeneca, Janssen, Merck, Novartis, Pfizer, Point Biopharma, Roche, BMS; Financial Interests, Institutional, Steering Committee Member: AstraZeneca, Janssen, Novartis, Roche; Financial Interests, Institutional, Trial Chair: AstraZeneca, Arvinas, Janssen, Novartis; Financial Interests, Institutional, Local PI: Arvinas. J.S. de Bono: Financial Interests, Personal, Advisory Board: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Eisai, Genentech Roche, Genmab, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals, Menarini Silicon Biosystems, ImCheck Therapeutics, Crescendo; Financial Interests, Institutional, Advisory Board: Harpoon; Financial Interests, Institutional, Research Grant: Astellas, AstraZeneca, Bayer, Cellcentric, Daiichi Sankyo, Genentech Roche, Genmab, GSK, Harpoon, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Sanofi Aventis, Sierra Oncology, Taiho, Vertex Pharmaceuticals, Crescendo Biologics, Menarini Silicon Biosystems; Non-Financial Interests, Principal Investigator: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Eisai, Genentech Roche, Genmab, GSK, Harpoon, Janssen, Menarini Silicon Biosystems, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals, Crescendo, ImCheck Therapeutics; Non-Financial Interests, Institutional, Product Samples: Daiichi Sankyo, Bayer, Merck Serono, AstraZeneca, Harpoon, Pfizer, Sierra Oncology, Genentech/Roche, Sanofi Aventis, GSK. K. Fizazi: Financial Interests, Institutional, Advisory Board: Astellas, Bayer, Janssen, AAA, MSD, AstraZeneca, Novartis/AAA, Pfizer, Daiichi Sankyo; Financial Interests, Institutional, Invited Speaker: Astellas, Bayer, Janssen, Sanofi, MSD, AstraZeneca, Novartis, Pfizer; Financial Interests, Personal, Advisory Board: Curevac, Orion; Financial Interests, Personal, Advisory Board, February 2022: Arvinas; Financial Interests, Personal, Advisory Board, April 2022: Macrogenics; Financial Interests, Institutional, Research Grant, Trial chair: Pfizer, Bayer, AstraZeneca, Orion, MSD, BMS, Janssen; Non-Financial Interests, Principal Investigator, Chair of the 7DX phase 3 trial: BMS; Non-Financial Interests, Principal Investigator, Chair of the Docetaxel-pembrolizumab phase 3 trial: Merck; Non-Financial Interests, Principal Investigator, Chair of the Darolutamide BCR phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the PSMAfore phase 3 trial: AAA/Novartis; Non-Financial Interests, Principal Investigator, Chair of the CYPIDES ODM-208 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the STESIDES ODM-209 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the CAPITELLO 281 phase 3 trial: AstraZeneca; Non-Financial Interests, Principal Investigator, Chair of the TALAPRO-2 and TALAPRO-3 phase 3 trials: Pfizer; Non-Financial Interests, Principal Investigator, Chair of the RADIANT phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the TRITON-3 phase 3 trial: Clovis. B. Krause: Financial Interests, Personal, Funding: Novartis; Financial Interests, Personal, Speaker, Consultant, Advisor: Terumo, Novartis, PSI CRO, ITM, Astellas, Janssen; Financial Interests, Personal, Advisory Board: ITM, Bayer Vital, Janssen, Novartis, Terumo. K. Herrmann: Financial Interests, Personal, Advisory Board: Bayer, Adacap/Novartis, Curium, Boston Scientific, GE Healthcare, AstraZeneca; Financial Interests, Personal, Invited Speaker: Sirtex, Siemens Healthineers, Monrol; Financial Interests, Personal, Other, Consultant: Amgen; Financial Interests, Personal, Other, DMSB: ymabs; Financial Interests, Personal, Advisory Board, Scientific Advisor: AdvanceCell; Financial Interests, Personal, Advisory Board, Advisor, Consultant: Janssen; Financial Interests, Personal, Advisory Board, Consultant: Eco1R; Financial Interests, Personal, Member of Board of Directors: Sofie Biosciences, Theragnostics, Pharma 15; Financial Interests, Personal, Ownership Interest: Sofie Biosciences; Financial Interests, Personal, Stocks/Shares: Aktis Oncology; Non-Financial Interests, Leadership Role, Chair Oncology&Theragnostics Committee: EANM. K. Rahbar: Financial Interests, Personal and Institutional, Advisory Role: ABX, Bayer; Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: AAA; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Janseen Cilag, Amgen; Financial Interests, Personal, Advisory Role: ABX CRO, Pharmatrace. S.T. Tagawa: Financial Interests, Personal, Advisory Board: Convergent Therapeutics, AIkido Pharma; Financial Interests, Personal, Other, Consultant: EMD Serono, Telix Pharma, Blue Earth Diagnostics, POINT Biopharma, Myovant, Bayer, 4D Pharma, Gilead, Pfizer, Janssen, Astellas, AbbVie, Novartis, Seagen, Clarity, Merck, Myovant, EMD Serono; Financial Interests, Personal, Stocks/Shares: AIkido Pharma; Financial Interests, Personal, Other, Patent co-inventor: Gilead; Financial Interests, Institutional, Local PI: Medivation, Astellas, Janssen, Amgen, BMS, AstraZeneca, Bayer, Merck, Clovis, Seagen; Financial Interests, Institutional, Steering Committee Member: Gilead, Novartis, POINT Biopharma, Clarity, Ambrx, Promontory. M.J. Morris: Financial Interests, Personal, Advisory Board: Oric, Pfizer, Exelixis, Lantheus, AstraZeneca, Amgen, Daiichi Sankyo, Convergent, Clarity Pharmaceuticals, Blue Earth Diagnostics, POINT Biopharma, Telix, Z-alpha; Financial Interests, Personal, Invited Speaker: Progenics, ITM Isotope Technologies; Financial Interests, Personal, Stocks/Shares: Doximity; Financial Interests, Institutional, Coordinating PI: Novartis, Celgen; Financial Interests, Institutional, Local PI: Corcept, Janssen, Astellas; Non-Financial Interests, Advisory Role: Bayer, Janssen Oncology, Novartis; Other, Other, Travel to conference: AstraZeneca; Other, Other, Travel/lodging at conference: APCCC. A. Meisel: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Amgen, Astellas, Boehringer Ingelheim, Celgene, Janssen, Gerresheimer, GSK, Merck, MSD, Novartis, Roche, Regeneron, Sanofi, Servier, Takeda, Vifor, Daiichi Sankyo; Financial Interests, Personal and Institutional, Research Funding: Bayer, Merck & Cie; Financial Interests, Personal, Expert Testimony: Sanofi; Financial Interests, Personal, Funding: Amgen, Astellas, Boehringer Ingelheim, Janssen, Merck, Roche, Sanofi, Servier, Takeda; Financial Interests, Personal, Licencing Fees or royalty for IP: Merck. G. Holder: Financial Interests, Personal, Stocks or ownership: Novartis, Aclon, Santhera; Financial Interests, Personal, Full or part-time Employment: Advanced Accelerator Applications, Novartis. J. Wu: Financial Interests, Personal, Full or part-time Employment: Novartis; Financial Interests, Personal, Stocks/Shares: Novartis. O. Sartor: Financial Interests, Personal, Speaker, Consultant, Advisor: Advanced Accelerator Applications, Amgen, ArtBio, Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Clarity, Clovis, Constellation, Convergent, Dendreon, EMD Serono, Foundation Medicine, Fusion, Hengrui, Isotopen Technologien Meunchen, Janssen, Merck, Morphimmune, Myovant, Myriad, NorthStar, Novartis, PointBiopharma, Pfizer, RATIO, Sanofi, TELIX, Theragnoscics; Financial Interests, Institutional, Research Grant: Advanced Accelerator Applications, Amgen, Bayer, Constellation, Janssen, Merck; Non-Financial Interests, Institutional, Research Grant: Endocyte, Invitae, Progenics, Tenebio; Non-Financial Interests, Personal, Speaker, Consultant, Advisor: Genzyme, Noria Therapeutics, Inc, Noxopharm, Progenics, Tenebio, Tessa, Z-alpha; Financial Interests, Personal, Stocks/Shares: RATIO; Financial Interests, Institutional, Stocks/Shares: TELIX. All other authors have declared no conflicts of interest.
Resources from the same session
1841TiP - Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)
Presenter: Alicia Morgans
Session: Poster session 15
1842TiP - Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)
Presenter: Johann de Bono
Session: Poster session 15
1922P - Immunosarc II master trial: phase II of sunitinib and nivolumab in vascular sarcomas cohort - A GEIS, ISG and UCL study
Presenter: Nadia Hindi Muñiz
Session: Poster session 15
1923P - Combined analysis of phase III ANNOUNCE study and phase II study exploring olaratumab in advanced soft tissue sarcoma
Presenter: Yoichi Naito
Session: Poster session 15
1924P - Targeting microenvironment and cellular immunity in sarcomas with trabectedin combined with metronomic cyclophosphamide: The TARMIC study
Presenter: Cheng-Ming Sun
Session: Poster session 15
1925P - Results of SOC-2082 phase II study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab as second/third-line therapy for advanced leiomyosarcoma
Presenter: Neal Chawla
Session: Poster session 15
1926P - Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study
Presenter: Javier Martin-Broto
Session: Poster session 15
1927P - Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
Presenter: Axel Le Cesne
Session: Poster session 15
1928P - Differential presentation and outcome of sclerosing epithelioid fibrosarcoma (SEF) vs low grade fibromyxoid sarcoma (LGFMS): The nationwide series of 330 patients in NETSARC since 2010
Presenter: Jean-Yves Blay
Session: Poster session 15
1929P - phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 15